HR+/HER2- advanced or metastatic breast cancer Archives

U.S. FDA approves LYNPARZA as adjuvant treatment for patients with gBRCAm HER2-negative high-risk early breast cancer

Approvals, AstraZeneca, Blockbusters, BRCA mutation, Business, Collaborations, FDA, gBRCAm HER2-negative high-risk early breast cancer, HR+/HER2- advanced or metastatic breast cancer, Merck, New Indications, Oncology, Therapeutics

AstraZeneca and Merck & Co. Inc. announced Lynparza (olaparib) was approved in the United States for the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer who have already been treated with chemotherapy either before or after surgery.

Novartis says Kisqali boosts survival in breast cancer patients

Advanced Breast Cancer, Analysts, Blockbusters, European Society for Medical Oncology (ESMO), HR+/HER2- advanced or metastatic breast cancer, Menopause, Overall Survival (OS), Polls

Novartis said Kisqali helped women with advanced breast cancer after menopause live longer, adding to data the Swiss company hopes will help convince doctors to choose the drug over Pfizer’s blockbuster Ibrance.

Novartis’ Kisqali Effective in Postmenopausal Women with Breast Cancer

Breast Cancer, CAR-T Therapy, Clinical Trials, HR+/HER2- advanced or metastatic breast cancer, Overall Survival (OS), Payers, Postmenopausal, R&D

Novartis’ Phase III MONALEESA-3 clinical trial of Kisqali (ribociclib) hit the key secondary endpoint, overall survival.